

RECEIVED
CENTRAL FAX CENTER

FEB 19 2004

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:	FAX NUMBER:
Examiner Robert Mondesi	(703) 872-9306
USPTO	
FROM:	PHONE NUMBER:
Palaiyur S. Kalyanaraman	(908) 298-5068
TOTAL NO. OF PAGES INCLUDING COVER	DATE
40	February 19, 2004

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:


PLEASE HAND DELIVER

In re Application of: Kevin X. Chen *et al.*
For Patent entitled: "Macrocyclic NS3-Serine Protease Inhibitors of Hepatitis C Virus
Comprising N-Cyclic P2 Moieties"
Group Art Unit: 1653
Filed: 04/03/2001
Attorney Docket No.: IN01154K US
Serial No.: 09/825,399

Dear Examiner Mondesi:

Transmitted herewith are:

- Non-Fee Amendment – 38 Pages
- Certificate of Transmission – PTO/SB/97 – 1 Page
- Fax Cover Sheet – 1 Page


Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

PHONE: (908) 298-5068

FAX: (908) 298-5388

Attorney Docket No.: IN01154K

Application No.: 09/825,399

Filing Date: 04/03/2001

First Named Inventor: Kevin X. Chen

PTO/SB/97 (09-03)

Approved for use through 07/31/2006, OMB 0551-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-872-9306)

on 02/19/2004

Date



Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

Non-Fee Amendment - 38 Pages

Certificate of Transmission - 1 Page

Fax Cover Sheet - 1 Page

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

PATENT CASE: IN01154K

FEB 19 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE-----X
In re Application of:Chen *et al*

Serial No.: 09/825,399

Filed: April 3, 2001

For: "Macrocyclic NS3-Serine Protease :
Inhibitors of Hepatitis C Virus :
Comprising N-Cyclic P2 Moieties" :
-----X

Examiner: R. Mondesi

Group Art Unit: 1653

Atty. Docket No.: IN01154K

Mail Stop: Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450AMENDMENT

Sir:

This communication is in response to the Office Action that the Examiner issued on December 15, 2003, in the above-identified patent application. This communication is being faxed to the Examiner's attention at 703-872-9306.

Claims 1-25, 27 and 31-36, along with any rejoined portions of claims 28-30, are pending in the case. Applicant respectfully requests entry of the following Amendment.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 37 of this paper.